share_log

HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $2 Price Target

Benzinga Real-time News ·  Feb 3, 2023 01:21

HC Wainwright & Co. analyst Vernon Bernardino reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $2 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment